Boston Scientific Expects Q4 Organic Revenue Decline
Boston Scientific expects a fourth-quarter organic revenue decline within the stated range.
Related stories
Ningbo Zhoushan Port Q3 Net Profit Falls 17.16% Y/Y
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Nasdaq Futures Fall 1% as Alphabet Results Fuel AI Spending Fears
Nasdaq futures fell 1% as Alphabet's results intensified concerns about AI spending. Dow futures were up 0.5.
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC
Schneider Electric Infrastructure to Expand Vacuum Interrupter Capacity
Schneider Electric Infrastructure plans to increase vacuum interrupter capacity from 250,000 to 375,000 units per annum.
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC
Acwa-EIG Joint Venture Targets $4 Billion Investment in US Power Sector
Saudi Arabia’s Acwa said its joint venture with EIG targets $4 billion in investment in the US power sector.
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC
Montage Technology Says Q3 Revenue Rose 46% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC
Spring Airlines says Q3 revenue rose 8.5% year over year
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC